Affiliation:
1. Department of Clinical Microbiology, Zibo City Key Laboratory of Respiratory Infection and Clinical Microbiology, Zibo City Engineering Technology Research Center of Etiology Molecular Diagnosis
2. Department of Pulmonary and Critical Care Medicine, Zibo Municipal Hospital
Abstract
AbstractBackground:Immunotherapy is an indispensable treatment in advanced lung adenocarcinoma (LUAD). However, only a small percentage of patients have experienced the specificity and effectiveness of immune checkpoint inhibitors. To maximize the therapeutic benefits for LUAD patients, a bioinformatics analysis was used to validate a prognostic signature for LUAD based on immune-related genes.Methods:RNA sequence and clinical information of LUAD patients were taken from the TCGA database. Microarray datasets of GSE30219, GSE72094, and GSE37745 and their survival information were downloaded from the GEO database and the prognostic signature was verified through GEO external validation cohorts. Finally, TIDE, immune checkpoint molecules and two independent external immunotherapy validation cohorts (GSE91061 and Imvigor210) were analyzed to evaluate immunotherapy efficacy.Results:We constructed an immune-related diagnostic signature and verified the prognostic value in TCGA, GSE30219, GSE72094, and GSE37745. The gene sets of high-risk samples were correlated with cell cycle, DNA replication, ribosome, and steroid hormone biosynthetic pathway,SPTA1mutation rate, and lower benefit from ICI therapy; whereas the low-risk patients were correlated with intestinal immune network for IgA production, FLGgene mutation rate, and higher benefit from ICI therapy.Conclusions:The immune-related gene signature for LUAD may have prognostic relevance in ICI therapy.
Publisher
Research Square Platform LLC
Reference32 articles.
1. Genome-wide analysis of DNA methylation and their associations with long noncoding RNA/mRNA expression in non-small-cell lung cancer[J];Feng NN;Epigenomics,2017
2. Safety, activity, and immune correlates of anti PD-L1 antibody in cancer[J];Topalian SL;N Engl J Med,2012
3. Global cancer statistics, 2012[J];Torre LA;CA Cancer J Clin,2015
4. Cancer registration in China and its role in cancer prevention and control[J];Wei W;Lancet Oncol,2020
5. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-Mutant lung cancer[J];Calles A;J Thorac Oncol,2015